The U.S. Food and Drug Administration (FDA) has approved Movantik (naloxegol) tablets drugs that are used for the treatment of constipation, Nektar Therapeutics (NASDAQ:NKTR) has said. In the statement, the pharmaceuticals company announced that the drug has successfully gone through the agency’s approval intricacies to attain their approval as a treatment of constipation caused by…
Gilead Sciences, Inc. (GILD) Strikes Deal for Cheaper Hepatitis C Drugs for Developing Countries
Developing countries will soon receive cheaper hepatitis C drugs; thanks to a deal Gilead Sciences, Inc. (NASDAQ:GILD) signed with Indian companies to develop generic versions of the drug. The deal allows the companies to make sofusbivir, which is sold under the name Sovaldi, and sell it in 91 specified countries. The drug costs $1,000 a…
Avanir Pharmaceuticals Inc (AVNR)’s Shares Touch New Heights on Successful Trial Results
The shares of Avanir Pharmaceuticals Inc (NASDAQ:AVNR) have soared after successful Phase II clinical trial results of AVP-923, which was successful in reducing the agitation of patients suffering from Alzheimer. Avanir Pharmaceuticals Inc (NASDAQ:AVNR) share prices soared by $5.75 and closed after a hike of 85.31 percent. According to the official press release from Avanir…
Gilead Sciences, Inc. (GILD) Raises the New Hepatitis C Drug Price to Above $84,000
Gilead Sciences, Inc. (NASDAQ:GILD) is already being attacked for the unbelievable price tag for the next generation oral hepatitis C drug, which is expected to be released next month. Currently, full treatment of the hepatitis C virus costs $95,000; a subscription that includes Sovaldi, ribavirin and interferon. The next generation drug to be released is…
Amarin Corporation plc (ADR) (AMRN) Stocks Plummet After SPA Denial from FDA
The shares of Amarin Corporation plc (ADR) (NASDAQ:AMRN) fell as much as 17.68% after its announcement about the denial of its FDA rescission of the ANCHOR clinical trial Special Protocol Assessment (SPA) agreement. The Office of New Drugs (OND) working under the Food and Drug Administration Department (FDA) denied Amarin Corporation plc (ADR) (NASDAQ:AMRN)’s appeal.…
GlaxoSmithKline plc (ADR) (GSK) Might Face Legal Trouble in Chinese Consumer Healthcare Unit
GlaxoSmithKline plc (ADR) (NYSE:GSK) could be involved in breaking an anti-bribery law in its Chinese consumer healthcare unit and the probe might raise some legal concerns for the company. GlaxoSmithKline plc (ADR) (NYSE:GSK) faced a U.S. anti-bribery inquiry in 2012, as indicated in its internal documents. Further, even the company did an internal investigation to…
GlaxoSmithKline plc (ADR) (GSK) Vaccine for Ebola Exhibits Positive Results in Monkey Tests
With Ebola affecting a vast population in West Africa, there is some good news from GlaxoSmithKline plc (ADR) (NYSE:GSK) as it has successfully tested its Ebola Vaccine on Monkeys. The test included monkeys with Ebola infection and after giving the experimental drug, the monkey didn’t develop any signs of the deadly virus. As per the…
Gilead Sciences, Inc. (GILD) to Offer Low-cost Versions of Hepatitis C in lower economies
In a scintillating string of events, Gilead Sciences, Inc (NASDAQ:GILD) is in talks with generic drug makers to offer a low-cost versions of its premium $84,000 Hepatitis C treatment, Sovaldi, in developing countries including India, Pakistan, Indonesia, and nearly 80 countries. Gilead Sciences, Inc (NASDAQ:GILD) offers Sovaldi treatment at a cost of $84,000 in the…
CVS Caremark Corporation (CVS) Halts Tobacco Sale and Modifies Name
CVS Caremark Corporation (NYSE:CVS), one of the leading drugstores, had announced in February this year that it would stop cigarette sales in its stores October, but has pulled a surprise by directing a withdrawal a month before the scheduled date. The company is also said to be making a change to its name in a…
Google-Funded Calico Resources Corp (CKB) and AbbVie Inc (ABBV) to Jointly Launch a $1.5 Billion Aging Research Center
Calico Resources Corp (CVE:CKB), a company funded by Google Inc(NASDAQ:GOOG), and biopharmaceutical firm, AbbVie Inc (NYSE:ABBV), have announced a partnership to set up a research and development center. Cnet has said in an article that the two companies will be contributing the amount equally with the upfront being $250 million each. The balance will then…